Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hutchmed China Ltd ADR (HCM)

Hutchmed China Ltd ADR (HCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,725,159
  • Shares Outstanding, K 174,466
  • Annual Sales, $ 630,200 K
  • Annual Income, $ 37,730 K
  • EBIT $ 0 M
  • EBITDA $ -31 M
  • 60-Month Beta 0.42
  • Price/Sales 4.55
  • Price/Cash Flow 55.88
  • Price/Book 2.25

Options Overview Details

View History
  • Implied Volatility 213.38% (+107.83%)
  • Historical Volatility 33.86%
  • IV Percentile 78%
  • IV Rank 54.80%
  • IV High 332.46% on 12/15/25
  • IV Low 69.01% on 03/24/25
  • Expected Move (DTE 30) 1.70 (10.73%)
  • Put/Call Vol Ratio 4.00
  • Today's Volume 5
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 315
  • Open Int (30-Day) 285
  • Expected Range 14.15 to 17.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.13 +20.72%
on 12/30/25
16.33 -2.94%
on 01/16/26
+2.30 (+16.97%)
since 12/19/25
3-Month
13.06 +21.33%
on 12/16/25
16.33 -2.94%
on 01/16/26
+0.65 (+4.28%)
since 10/21/25
52-Week
11.51 +37.71%
on 04/09/25
19.50 -18.72%
on 07/29/25
+1.64 (+11.54%)
since 01/21/25

Most Recent Stories

More News
Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX) and HUTCHMED (HCM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bicara Therapeutics Inc. (BCAX – Research Report) and HUTCHMED (HCM – Research Report) with bullish...

HCM : 15.85 (+1.47%)
BCAX : 16.97 (+1.50%)
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc.

ONCY : 1.1700 (+18.11%)
IDYA : 36.01 (+0.73%)
HCM : 15.85 (+1.47%)
CGON : 57.13 (+4.46%)
CCCC : 2.12 (-2.75%)
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

/CNW/ -- USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development...

ONCY : 1.1700 (+18.11%)
IDYA : 36.01 (+0.73%)
HCM : 15.85 (+1.47%)
CGON : 57.13 (+4.46%)
CCCC : 2.12 (-2.75%)
Best Momentum Stock to Buy for August 19th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 19th:Century Aluminum CENX: This company which is engaged in the production of primary aluminum...

CENX : 47.75 (-0.25%)
HCM : 15.85 (+1.47%)
MC : 76.71 (+2.54%)
HUTCHMED Granted Breakthrough Therapy Designation for Combination of ORPATHYS® and TAGRISSO® in Treating Advanced Non-Small Cell Lung Cancer

HUTCHMED announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® combination for advanced lung cancer.Quiver AI SummaryHUTCHMED has received Breakthrough Therapy Designation from...

HCM : 15.85 (+1.47%)
HUTCHMED and Innovent Announce First Regulatory Approval of Fruquintinib Combination Therapy with Sintilimab for Advanced Endometrial Cancer in China

HUTCHMED and Innovent announced conditional approval for fruquintinib plus sintilimab combination therapy for advanced endometrial cancer in China.Quiver AI SummaryHUTCHMED and Innovent Biologics have...

HCM : 15.85 (+1.47%)
HUTCHMED Announces Renewal of Inclusion for ORPATHYS® in China's National Reimbursement Drug List Effective January 1, 2025

HUTCHMED announces ORPATHYS® will remain on China's National Reimbursement Drug List following contract renewal with NHSA.Quiver AI SummaryHUTCHMED (China) Limited announced that ORPATHYS® (savolitinib)...

HCM : 15.85 (+1.47%)
HUTCHMED Receives Milestone Payment as FRUZAQLA® Launches in Japan for Metastatic Colorectal Cancer

HUTCHMED announces FRUZAQLA® launch in Japan for metastatic colorectal cancer after regulatory approval and milestone payment from Takeda.Quiver AI SummaryHUTCHMED has announced the approval and launch...

HCM : 15.85 (+1.47%)
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

ONCY : 1.1700 (+18.11%)
BGNE : 184.71 (+0.49%)
HCM : 15.85 (+1.47%)
ABBV : 216.15 (+0.99%)
ONC.TO : 1.42 (+2.16%)
ELVN : 27.20 (+0.55%)
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...

ONCY : 1.1700 (+18.11%)
BGNE : 184.71 (+0.49%)
HCM : 15.85 (+1.47%)
ABBV : 216.15 (+0.99%)
ONC.TO : 1.42 (+2.16%)
ELVN : 27.20 (+0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

HUTCHMED Limited is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. HUTCHMED Limited, formerly known as HUTCHMED...

See More

Key Turning Points

3rd Resistance Point 16.54
2nd Resistance Point 16.22
1st Resistance Point 16.04
Last Price 15.85
1st Support Level 15.54
2nd Support Level 15.22
3rd Support Level 15.04

See More

52-Week High 19.50
Fibonacci 61.8% 16.45
Last Price 15.85
Fibonacci 50% 15.51
Fibonacci 38.2% 14.56
52-Week Low 11.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar